Trademarks and Copyright© The images and information contained in the Site are, to the fullest extent possible, copyrighted and otherwise proprietary. It is the policy of Taro to enforce its intellectual property rights to the fullest extent of the law, including (where applicable) seeking criminal sanctions.

Investor Relations
Corporate Profile
Welcome to Taro’s Investor Relations Website
Established in 1950, Taro Pharmaceutical Industries Ltd. is a multinational science-based pharmaceutical company that develops, manufactures and markets generic and branded prescription and over-the-counter (OTC) pharmaceutical products. Taro’s research programs and niche strategy have enabled the Company to achieve leadership in dermatological products in the United States.

Business Overview
Taro develops, manufactures and markets prescription and OTC pharmaceutical products primarily in the United States, Canada and Israel. Taro’s primary areas of focus include pediatric creams and ointments, liquids, capsules and tablets, mainly for the dermatological, topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories.

TARO (Common Stock)
ExchangeNYSE Arca (US Dollar)
Change (%) Stock is Down 2.19 (2.42%)
Data as of 12/14/18 4:02 p.m. ET
Click Here for Stock Quote Data on NYSE

Shareholder Letter with Procedures Regarding Israeli Withholding Tax on Special Dividend payable December 28, 2018

Recent NewsMore >>
12/07/18Taro Provides Shareholders with Procedures Regarding Israeli Withholding Tax on DividendPrinter Friendly Version
11/05/18Taro Provides Results for September 30, 2018Printer Friendly Version
10/29/18Taro to Announce Second Quarter Results on November 5, 2018Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Terms of Use
Privacy Statement
Safe Harbor Statement